BCL2 and cancer: Mechanistically, SF3A3 promotes the alternative splicing of c‐FOS, a proto‐oncogene implicated in cancer progression, leading to increased full‐length c‐FOS expression and upregulation of the anti‐apoptotic Bcl2/Bax ratio.